In an elderly woman with stage IIIA (T2a N2 M0) non‑small cell lung cancer involving mediastinal stations 4R and 7, does her age change the recommended treatment plan, and how would comprehensive molecular profiling (including MET exon 14‑skipping, EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, RET, NTRK) influence management?

Impact of Age and Molecular Testing on Stage IIIA NSCLC Management

Age alone should not change your treatment approach—functional status, performance status, and comorbidities matter far more than chronological age in determining treatment intensity for this elderly woman with stage IIIA NSCLC. 1, 2

Age Does Not Alter Core Treatment Principles

Treatment decisions must be based on functional status, comorbidities, and life expectancy—not chronological age alone. Performance status 0-1 elderly patients should receive the same aggressive curative approach as younger patients. 3, 4

Key Evidence on Age and NSCLC Biology

• The biology of NSCLC does not differ between elderly and younger patients—disease-free survival and recurrence rates are equivalent across age groups when adjusted for performance status. 1

• Age had no independent impact on prognosis in multivariate analyses of resected NSCLC patients. 1

• The only consistent differences in elderly patients are higher rates of anemia and worse performance status, which reflect comorbidities rather than tumor biology. 1

Critical Caveat for Elderly Patients

• Elderly patients (≥75 years) receiving neoadjuvant chemotherapy experience significantly higher postoperative complications with no demonstrated mortality benefit compared to younger patients. 3, 4

• For elderly patients with stage IIIA disease, proceed directly to surgical resection if pulmonary function is adequate, then base adjuvant therapy decisions on pathologic findings rather than using neoadjuvant approaches. 3

How Molecular Testing Guides Management

Comprehensive molecular profiling fundamentally changes treatment strategy by identifying targetable alterations that may offer superior outcomes to standard chemotherapy, particularly in elderly patients who tolerate targeted therapies better than cytotoxic chemotherapy. 2, 5

Actionable Alterations and Their Clinical Impact

MET exon 14-skipping mutations:

• Present in 1.3-3% of NSCLC, with higher prevalence in elderly patients (median age 73 years) and those without other driver mutations. 6, 7, 8

• MET-TKI therapy (capmatinib or tepotinib) yields progression-free survival of 5.4-12.4 months in advanced disease, providing a targeted alternative to chemotherapy. 8, 5

• If MET exon 14-skipping is detected, this patient would be a candidate for MET-TKI therapy in the adjuvant or recurrent setting rather than standard chemotherapy. 5

EGFR mutations:

• Elderly patients (≥70 years) have slightly lower rates of EGFR high-polysomy compared to younger patients, but testing remains essential. 1

• EGFR-TKIs demonstrate superior tolerability in elderly patients compared to chemotherapy and are the preferred first-line treatment when mutations are present. 2, 5

ALK, ROS1, RET, and NTRK fusions:

• These alterations are mutually exclusive with other drivers and dictate use of specific targeted therapies with better efficacy and tolerability profiles than chemotherapy. 2, 5

• ALK inhibitors are particularly effective for brain metastases, potentially delaying or avoiding whole-brain radiation. 2

BRAF V600E and KRAS G12C mutations:

• BRAF V600E mutations respond to combination dabrafenib/trametinib therapy. 5

• KRAS G12C mutations are targetable with sotorasib or adagrasib, offering options beyond chemotherapy. 5

Why Molecular Testing is Essential in This Case

Co-mutations frequently occur with MET alterations:

• 78-94% of MET exon 14-skipping tumors have EGFR and/or HER2 gene copy number gains, which may influence treatment selection. 7

• Common co-mutations include TP53 (22%), KRAS (8%), BRAF (21%), and PIK3CA (~14%), which can affect prognosis and treatment response. 9, 8

Treatment tolerance considerations:

• Elderly patients tolerate targeted therapies significantly better than platinum-based chemotherapy, making identification of actionable mutations particularly valuable in this population. 2

• If no actionable mutation is found, adjuvant chemotherapy demonstrates survival benefit in elderly patients with tolerability similar to younger patients (<70 years), but only after adequate surgical recovery. 3, 4

Practical Algorithm for This Patient

1. Complete comprehensive molecular profiling immediately (EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, RET, NTRK, MET exon 14-skipping). 2, 5

2. Assess surgical candidacy through pulmonary function testing (VO2 max ≥15 ml/kg/min AND FEV1 >35% predicted). 3

3. Proceed to surgical resection (lobectomy via VATS when possible, avoiding pneumonectomy) if pulmonary function adequate. 3, 4

4. Base adjuvant therapy on molecular results and pathologic staging:

   • If actionable mutation present → targeted therapy
   • If no actionable mutation and pathologic N2 disease confirmed → platinum-based adjuvant chemotherapy after adequate recovery
   • If pathologic N0 disease → no adjuvant therapy needed 3, 4

The molecular profile determines whether this elderly patient receives targeted therapy (better tolerated) versus chemotherapy (more toxic), making it a critical determinant of treatment intensity and quality of life. 2, 5